Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 51.97% | 18.54% | 30.44% | 40.22% | 56.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.97% | 18.54% | 30.44% | 40.22% | 56.99% |
| Cost of Revenue | 18.59% | 0.34% | -2.87% | 16.08% | 33.43% |
| Gross Profit | 87.71% | 34.02% | 64.41% | 64.50% | 93.49% |
| SG&A Expenses | 65.47% | 47.99% | 10.77% | -25.08% | -48.81% |
| Depreciation & Amortization | -46.49% | -28.28% | -12.09% | 1.05% | 5.95% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.78% | 34.93% | 14.37% | -9.63% | -35.94% |
| Operating Income | -36.76% | -41.86% | -9.68% | 19.59% | 47.19% |
| Income Before Tax | -60.18% | -67.98% | -47.17% | -10.74% | 64.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -60.18% | -67.98% | -47.17% | -10.74% | 64.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.18% | -67.98% | -47.17% | -10.74% | 64.11% |
| EBIT | -36.76% | -41.86% | -9.68% | 19.59% | 47.19% |
| EBITDA | -64.51% | -60.68% | -10.66% | 27.81% | 57.86% |
| EPS Basic | -41.41% | -54.39% | -39.34% | -8.19% | 63.48% |
| Normalized Basic EPS | -27.04% | -37.32% | -23.03% | 5.71% | 35.89% |
| EPS Diluted | -41.41% | -54.39% | -39.34% | -8.19% | 63.05% |
| Normalized Diluted EPS | -27.04% | -37.32% | -23.03% | 5.71% | 35.89% |
| Average Basic Shares Outstanding | 15.29% | 10.26% | 5.63% | 1.27% | -0.51% |
| Average Diluted Shares Outstanding | 15.29% | 10.26% | 5.63% | 1.27% | -0.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
